Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Announces Amendment to Credit Agreement for U.S. Dollar Term Loans
Summary
Jazz Pharmaceuticals plc announced on July 19, 2024, an amendment to its Credit Agreement for repricing the U.S. dollar term loan B-1 facility, converting existing loans into a new tranche of U.S. dollar term loans (Tranche B-2). The amendment resulted in borrowing $289,564,455.52 in additional Tranche B-2 Dollar Term Loans to repay the Tranche B-1 Dollar Term Loans that were not converted. The new tranche bears interest at a lower margin, with the interest rate set at either Term SOFR or the prime lending rate plus a margin of 2.25% or 1.25%, respectively. The Tranche B-2 Dollar Term Loans will amortize quarterly and are payable in full on May 5, 2028.
Profitelligence Alerts
Get alerts for JAZZ
Be first to know when Jazz Pharmaceuticals plc files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Official SEC Documents
Advertisement